Pharmaceutical developer Avacta Group (LSE:AVCT), also known as AVCT, is one of the UK’s leading diagnostics and cancer therapies, but has seen its share price plummet by a staggering 63% in 2024. This dramatic decline has left many investors wondering what has triggered this downward spiral in the AVCT ...
motleyfooluklse:avct